Clinical trial
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00088049 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00088049 |
|---|---|
| Title | Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia |
| Official title | A Randomized Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine, Aripiprazole |
| Enrollment | 560 |
| Start date | Oct 1, 2003 |
| Completion | Jul 1, 2007 |
| First posted | Jul 21, 2004 |
| Last update posted | Jul 18, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: